The well-publicized growth of the diabetic population worldwide has created market opportunity for therapies that address three microvascular complications of diabetes: nephropathy, neuropathy, and retinopathy. Chronic hyperglycemia puts all diabetics at risk of developing these conditions, which can exact a considerable toll on the diabetic patient. Microvascular Complications of Diabetes, a new Decision Resources study, evaluates untapped opportunities in each market sector.
The marketplace for the three microvascular complications of diabetes consists of unique areas of varying opportunity and possible challenges:
* Diabetic retinopathy. This market is the most promising of the three under study. Protein-kinase-C inhibitors (such as Eli Lilly's LY- 333531) represent enormous market potential because the near lack of existing pharmacotherapy has kept drug-treated rates below 15%. Other emerging therapies such as somatostatin analogues will find their own niches in the treatment of patients in the early stages of retinopathy or those with atypical symptoms. Together, these agents will drive the retinopathy market to a phenomenal 25% annual growth from 2000 to 2010. * Diabetic neuropathy. Development of effective therapies for diabetic neuropathy has been plagued by failures and near misses, so the unmet need for effective therapies remains considerable. Although we anticipate seven new agents will find a niche in this market, they will make up just over 10% of the 2010 sales total. Fueled by their entrenched positions as first-line therapies, anticonvulsants and aldose reductase inhibitors (ARIs) will maintain their market dominance throughout the next decade, but a need will still exist for safe, effective, and (ideally) disease-modifying agents. * Diabetic nephropathy. The existence of effective antihypertensive therapies and a dearth of significant novel agents in development add up to a relatively stable market for diabetic nephropathy.
Microvascular Complications of Diabetes offers invaluable market intelligence for pharmaceutical companies competing in this market. This study is part of Mosaic, one of six Pharmacor services from Decision Resources that evaluate the commercial potential of drugs in research and development.
Macrovascular complications are discussed in the recent Decision Resources study Cardiovascular Complications of Diabetes.
Decision Resources, Inc., is a world leader in pharmaceutical research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. Founded as a subsidiary of Arthur D. Little, Inc., the company has provided strategic information services for 30 years. Visit the Decision Resources Web site at http://www.dresources.com/.
Contact: Frank Sama, 781.296.2553 (telephone), 781.296.2550 (fax), or email@example.com.
In Europe, contact Francoise Bidart, +32.2.351.4082 (telephone), +32.2.351.2347 (fax), or firstname.lastname@example.org.
In Japan, contact Makiko Yoshimoto, +81.3.5401.2615 (telephone), +81.3.5401.2617 (fax), or email@example.com.
AP Archive: http://photoarchive.ap.org/
PRN Photo Desk, 888-776-6555 or 212-782-2840
SOURCE: Decision Resources, Inc.
Contact: Frank Sama of Decision Resources, Inc., +1-781-296-2553,